James A. Fagin
About
James A. Fagin is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Molecular Biology.
According to data from OpenAlex, James A. Fagin has authored 242 papers receiving a total of 23.5k indexed citations (citations by other indexed papers that have themselves been cited), including 163 papers in Endocrinology, Diabetes and Metabolism, 99 papers in Oncology and 96 papers in Molecular Biology. Recurrent topics in James A. Fagin's work include Thyroid Cancer Diagnosis and Treatment (131 papers), Cancer-related Molecular Pathways (79 papers) and Growth Hormone and Insulin-like Growth Factors (27 papers). James A. Fagin is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (131 papers), Cancer-related Molecular Pathways (79 papers) and Growth Hormone and Insulin-like Growth Factors (27 papers). James A. Fagin collaborates with scholars based in United States, Italy and United Kingdom. James A. Fagin's co-authors include Jeffrey A. Knauf, Yuri E. Nikiforov, Ronald Ghossein, Marina N. Nikiforova, Samuel A. Wells, Zhaowen Zhu, Edna Teruko Kimura, Julio C. Ricarte‐Filho, R. Michael Tuttle and James S. Forrester and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.
In The Last Decade
James A. Fagin
240 papers receiving 23.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| James A. Fagin United States | 76 | 15.1k | 8.8k | 7.8k | 3.8k | 3.2k | 242 | 23.5k | ||
| Rossella Elisei Italy | 72 | 18.4k 1.2× | 4.5k 0.5× | 5.5k 0.7× | 3.4k 0.9× | 6.2k 1.9× | 370 | 23.3k | ||
| Yuri E. Nikiforov United States | 82 | 26.3k 1.7× | 7.3k 0.8× | 6.9k 0.9× | 6.0k 1.6× | 9.9k 3.1× | 250 | 32.8k | ||
| Manuel Sobrinho‐Simões Portugal | 65 | 7.2k 0.5× | 5.0k 0.6× | 3.6k 0.5× | 1.9k 0.5× | 4.4k 1.4× | 357 | 14.9k | ||
| Mingzhao Xing United States | 58 | 9.1k 0.6× | 6.2k 0.7× | 4.0k 0.5× | 2.3k 0.6× | 1.5k 0.5× | 120 | 13.9k | ||
| Samuel A. Wells United States | 62 | 8.1k 0.5× | 3.7k 0.4× | 4.7k 0.6× | 3.6k 0.9× | 3.9k 1.2× | 256 | 16.2k | ||
| Massimo Santoro Italy | 54 | 7.6k 0.5× | 4.4k 0.5× | 4.2k 0.5× | 1.8k 0.5× | 1.6k 0.5× | 114 | 11.6k | ||
| Marco A. Pierotti Italy | 85 | 4.4k 0.3× | 13.3k 1.5× | 10.7k 1.4× | 3.8k 1.0× | 2.6k 0.8× | 457 | 27.2k | ||
| Orlo H. Clark United States | 71 | 9.6k 0.6× | 3.0k 0.3× | 3.7k 0.5× | 3.2k 0.8× | 7.2k 2.2× | 347 | 17.1k | ||
| Electron Kebebew United States | 69 | 9.8k 0.6× | 3.8k 0.4× | 4.3k 0.6× | 2.4k 0.6× | 7.7k 2.4× | 378 | 19.1k | ||
| Bryan R. Haugen United States | 53 | 23.6k 1.6× | 3.9k 0.4× | 3.4k 0.4× | 3.7k 1.0× | 12.4k 3.9× | 159 | 27.7k |
Countries citing papers authored by James A. Fagin
Since
Specialization
Citations
This map shows the geographic impact of James A. Fagin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James A. Fagin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James A. Fagin more than expected).
Fields of papers citing papers by James A. Fagin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by James A. Fagin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James A. Fagin. The network helps show where James A. Fagin may publish in the future.
Co-authorship network of co-authors of James A. Fagin
This figure shows the co-authorship network connecting the top 25 collaborators of James A. Fagin. A scholar is included among the top collaborators of James A. Fagin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James A. Fagin. James A. Fagin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dong, Yiyu, Yongxing Gong, Fengshen Kuo, et al.. (2021). Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. Molecular Cancer Therapeutics. 21(2). 382–394.
2.
Saqcena, Mahesh, Luis J. Leandro‐García, Jesper L.V. Mååg, et al.. (2020). SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. Cancer Discovery. 11(5). 1158–1175.
3.
Fletcher, Alice, Martin L. Read, Dean P. Larner, et al.. (2019). Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake. Cancer Research. 80(1). 102–115.
4.
Landa, Iñigo, Nikita Pozdeyev, Christopher Korch, et al.. (2019). Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clinical Cancer Research. 25(10). 3141–3151.
5.
Schweppe, Rebecca E., Nikita Pozdeyev, Laura A. Pike, et al.. (2019). Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Molecular Cancer Research. 17(5). 1036–1048.
6.
Krishnamoorthy, Gnana P., Natalie R. Davidson, Steven D. Leach, et al.. (2018). EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. Cancer Discovery. 9(2). 264–281.
7.
Ibrahimpašić, Tihana, Bin Xu, Iñigo Landa, et al.. (2017). Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clinical Cancer Research. 23(19). 5970–5980.
8.
García-Rendueles, María E.R., Julio C. Ricarte‐Filho, Brian R. Untch, et al.. (2015). NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discovery. 5(11). 1178–1193.
9.
Landa, Iñigo, Ian Ganly, Timothy A. Chan, et al.. (2013). Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease. The Journal of Clinical Endocrinology & Metabolism. 98(9). E1562–E1566.
10.
Knauf, Jeffrey A., C. F. Gotfredsen, Andrew Pilling, et al.. (2012). GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation. Endocrinology. 153(3). 1538–1547.
11.
Couto, Joana, Laura Daly, Ana Paula de Almeida, et al.. (2012). STAT3 negatively regulates thyroid tumorigenesis. Proceedings of the National Academy of Sciences. 109(35). E2361–70.
12.
Wells, Samuel A., Bruce G. Robinson, Robert F. Gagel, et al.. (2011). Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology. 30(2). 134–141.
13.
Robbins, Richard J., et al.. (2011). Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH. The Journal of Clinical Endocrinology & Metabolism. 96(7). 2105–2111.
14.
Franco, Aime T., Roberta Malaguarnera, Samuel Refetoff, et al.. (2011). Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proceedings of the National Academy of Sciences. 108(4). 1615–1620.
15.
Ricarte‐Filho, Julio C., Mabel Ryder, Dhananjay Chitale, et al.. (2009). Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA , and AKT1. Cancer Research. 69(11). 4885–4893.
16.
Croyle, Michelle, Nagako Akeno, Jeffrey A. Knauf, et al.. (2008). RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR. Cancer Research. 68(11). 4183–4191.
17.
Schweppe, Rebecca E., Joshua Klopper, Christopher Korch, et al.. (2008). Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification. The Journal of Clinical Endocrinology & Metabolism. 93(11). 4331–4341.
18.
Mesa, Cléo Otaviano, M. B. Mirza, Norisato Mitsutake, et al.. (2006). Conditional Activation of RET/PTC3 and BRAFV600E in Thyroid Cells Is Associated with Gene Expression Profiles that Predict a Preferential Role of BRAF in Extracellular Matrix Remodeling. Cancer Research. 66(13). 6521–6529.
19.
Ouyang, Bin, Jeffrey A. Knauf, Eric P. Smith, et al.. (2006). Inhibitors of Raf Kinase Activity Block Growth of Thyroid Cancer Cells with RET/PTC or BRAF Mutations In vitro and In vivo. Clinical Cancer Research. 12(6). 1785–1793.
20.
Nikiforova, Marina N., Edna Teruko Kimura, Manoj Gandhi, et al.. (2003). BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas. The Journal of Clinical Endocrinology & Metabolism. 88(11). 5399–5404.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Rossella Elisei Breakdown of academic impact, for papers by Yuri E. Nikiforov Breakdown of academic impact, for papers by Manuel Sobrinho‐Simões Breakdown of academic impact, for papers by Mingzhao Xing Breakdown of academic impact, for papers by Samuel A. Wells Breakdown of academic impact, for papers by Massimo Santoro Breakdown of academic impact, for papers by Marco A. Pierotti Breakdown of academic impact, for papers by Orlo H. Clark Breakdown of academic impact, for papers by Electron Kebebew Breakdown of academic impact, for papers by Bryan R. Haugen